摘要
目的:探讨萘哌地尔(Naftop id il)治疗女性尿道综合征的有效性和安全性。方法:38例患者采用自身对照试验,洗脱期1周,治疗期4周,应用萘哌地尔片25mg,每晚口服。以尿道综合征症状评分(FUSS)为主要疗效指标,以生活质量评分(QOL)为次要观察指标。结果:治疗2周后患者症状开始好转,4周后疗效显著。治疗前后的FUSS、QOL相比较,差异显示均有统计学意义(P<0.01及P<0.05),总有效率为76.31%。结论:萘哌地尔治疗女性尿道综合征有效、安全。
Objective： To evaluate the efficacy and safety of Naftopidil on patients with female urethral syndrome （FUS）. Methods： Self-controlled clinical trial was performed in patients with FUS. Thirtyeight patients were treated with nafiopidil tablet 25mg/po/qn for 4 weeks after one-week washout period. The effects were evaluated mainly by female urethral syndrome score （FUSS） and quality of llfe （QOL）. Results： FUSS began to decrease after 2 week＇s administration and decreased significantly after 4 weeks ＇ treatment. It had statistically significant difference of FUSS and QOL after treatment compared with control （P 〈 0.01 or P 〈 0.05 ）. The total effective rate was 76.31%. Conclusion. Naftopidil was safe and effective in treating FUS.
出处
《医学研究生学报》
CAS
2005年第9期821-823,共3页
Journal of Medical Postgraduates
